Sweden
· Delayed Price · Currency is SEK Egetis Therapeutics AB Statistics
Total Valuation
Egetis Therapeutics AB has a market cap or net worth of SEK 2.37 billion. The enterprise value is 2.35 billion.
| Market Cap | 2.37B |
| Enterprise Value | 2.35B |
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Egetis Therapeutics AB has 359.24 million shares outstanding. The number of shares has increased by 29.11% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 359.24M |
| Shares Change (YoY) | +29.11% |
| Shares Change (QoQ) | -1.64% |
| Owned by Insiders (%) | 13.38% |
| Owned by Institutions (%) | 18.61% |
| Float | 210.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.29 |
| PB Ratio | 6.05 |
| P/TBV Ratio | 7.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.36 |
| EV / Sales | 34.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 0.35.
| Current Ratio | 0.98 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.59 |
Financial Efficiency
Return on equity (ROE) is -81.30% and return on invested capital (ROIC) is -42.12%.
| Return on Equity (ROE) | -81.30% |
| Return on Assets (ROA) | -34.12% |
| Return on Capital (ROIC) | -42.12% |
| Revenue Per Employee | 1.74M |
| Profits Per Employee | -8.19M |
| Employee Count | 28 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 415.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.93% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +8.93% |
| 50-Day Moving Average | 5.33 |
| 200-Day Moving Average | 5.90 |
| Relative Strength Index (RSI) | 59.82 |
| Average Volume (20 Days) | 1,081,202 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Egetis Therapeutics AB had revenue of SEK 67.90 million and -319.30 million in losses. Loss per share was -1.12.
| Revenue | 67.90M |
| Gross Profit | -139.60M |
| Operating Income | -303.40M |
| Pretax Income | -319.20M |
| Net Income | -319.30M |
| EBITDA | -299.80M |
| EBIT | -303.40M |
| Loss Per Share | -1.12 |
Balance Sheet
The company has 129.90 million in cash and 112.20 million in debt, giving a net cash position of 17.70 million or 0.05 per share.
| Cash & Cash Equivalents | 129.90M |
| Total Debt | 112.20M |
| Net Cash | 17.70M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 318.60M |
| Book Value Per Share | 1.09 |
| Working Capital | -2.60M |
Cash Flow
| Operating Cash Flow | -216.00M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -205.60% |
| Operating Margin | -446.83% |
| Pretax Margin | -470.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Egetis Therapeutics AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.11% |
| Shareholder Yield | -29.11% |
| Earnings Yield | -17.00% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Egetis Therapeutics AB has an Altman Z-Score of -1.3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.3 |
| Piotroski F-Score | n/a |